Acadia Pharmaceuticals
ACAD
354 hedge funds and large institutions have $4.27B invested in Acadia Pharmaceuticals in 2026 Q2 according to their latest regulatory filings, with 49 funds opening new positions, 136 increasing their positions, 113 reducing their positions, and 35 closing their positions.
67% more funds holding in top 10
Funds holding in top 10: 3 → 5 (+2)
40% more first-time investments, than exits
New positions opened: 49 | Existing positions closed: 35
20% more repeat investments, than reductions
Existing positions increased: 136 | Existing positions reduced: 113
16% more capital invested
Capital invested by funds: $3.67B → $4.27B (+$599M)
3% more funds holding
Funds holding: 343 → 354 (+11)
1.84% more ownership
Funds ownership: 96.68% → 98.52% (+1.8%)
5% more call options, than puts
Call options by funds: $6.66M | Put options by funds: $6.34M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
+$37.2M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$34.3M |
| 3 |
Qube Research & Technologies (QRT)
London,
United Kingdom
|
+$32.9M |
| 4 |
Goldman Sachs
New York
|
+$22.5M |
| 5 |
D.E. Shaw & Co
New York
|
+$21.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
First Trust Advisors
Wheaton,
Illinois
|
-$69.5M |
| 2 |
B
Braidwell
Stamford,
Connecticut
|
-$18.1M |
| 3 |
Jane Street
New York
|
-$15.2M |
| 4 |
WP
Woodline Partners
San Francisco,
California
|
-$15.1M |
| 5 |
FAM
Fred Alger Management
New York
|
-$13.8M |
ACAD Hedge Fund Activity: Q2 2026 in Review
354 of the 8,349 institutional investors tracked by Wall St. Rank reported a position in Acadia Pharmaceuticals (ACAD) for Q2 2026, worth a combined $4.27B — up 16% from $3.67B a quarter earlier.
Buyers outnumbered sellers: 49 funds opened new ACAD positions and 35 closed out — a net gain of 14 holders — while 136 added to existing stakes and 113 trimmed.
The largest buyer was Marshall Wace, adding an estimated $37.2M. The largest seller was First Trust Advisors, cutting an estimated $69.5M.
- 354 institutional investors held Acadia Pharmaceuticals (ACAD) as of Q2 2026, up from 343 in Q1 2026.
- Funds reported $4.27B of Acadia Pharmaceuticals stock for Q2 2026, up 16% quarter-over-quarter.
- 49 funds opened new Acadia Pharmaceuticals positions in Q2 2026 and 35 closed out, a net change of +14 holders.
- The largest Acadia Pharmaceuticals buyer in Q2 2026 was Marshall Wace, an estimated $37.2M added.
- The largest Acadia Pharmaceuticals seller in Q2 2026 was First Trust Advisors, an estimated $69.5M sold.
Based on aggregated 13F filings for Q2 2026.